Current trends in the management of myasthenia gravis: plasmapheresis and immunosuppressive therapy.
In recent years a considerable body of evidence has accumulated to demonstrate autoimmune mechanisms in myasthenia gravis. This evidence has important implications for the aetiology, diagnosis and management of the disease. The primary abnormality in myasthenia gravis is related to the presence of antibody which reacts with the acetylcholine receptor. Measurement of this IgG antibody in the serum has become the most reliable diagnostic adjunct to the edrophonium test, and in an individual patient, the level of the serum antibody relates closely to the clinical indices. In cases of myasthenia where control with anticholinesterase drugs is unsatisfactory, methods to lower the antiacetylcholine receptor antibody are indicated: these may include thymectomy, immunosuppressive therapy of plasmapheresis. Two patients with very severe disease are described in whom all types of therapy were used and in whom survival depended ultimately on the use of plasmapheresis. These patients illustrate the importance of receptor antibody in the clinical manifestations of myasthenia gravis and in its management.
D000109:Acetylcholine; D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007165:Immunosuppression Therapy; D009157:Myasthenia Gravis / Q000276:immunology / Q000628:therapy*; D010956:Plasmapheresis; D011955:Receptors, Drug / Q000276:immunology
D001323:Autoantibodies; D007074:Immunoglobulin G; D011955:Receptors, Drug; D000109:Acetylcholine